advanced search

EXPERT VIEW

THE END OF THE ROAD FOR pMDIs?
EXPERT VIEW
Finn Heraghty
THE END OF THE ROAD FOR pMDIs?
Finn Heraghty and Heather Jameson explore the extent to which the healthcare needs of a population could be covered by the combined use of soft mist inhalers and dry powder inhalers, and discuss the factors that will impact the continued importance of pressurised metered dose inhalers going forward.
TAKING A DRUG TO FIRST-IN-HUMAN TRIALS IN A BESPOKE DEVICE FOR TARGETED INTRANASAL DELIVERY
EXPERT VIEW
Dr Mark Allen
TAKING A DRUG TO FIRST-IN-HUMAN TRIALS IN A BESPOKE DEVICE FOR TARGETED INTRANASAL DELIVERY
Mark Allen, Andrew Fiorini and Shai Assia discuss the need to develop delivery devices early when formulating nasally delivered drugs for systemic and local action, and a method by which the route to clinic can be made easier, faster and cheaper. 
NASAL DRUG DELIVERY: OVERCOMING CHALLENGES WITH A ROBUST PLATFORM STRATEGY
EXPERT VIEW
Dr Richard Johnson
NASAL DRUG DELIVERY: OVERCOMING CHALLENGES WITH A ROBUST PLATFORM STRATEGY
Richard Johnson explores the changing nasal delivery landscape, highlighting challenges in nasal drug formulation and potential methods to overcome them.
THE IMPORTANCE OF THE BREATHING MANOEUVRE IN NEBULISED THERAPIES
EXPERT VIEW
Dr Carolina Dantas
THE IMPORTANCE OF THE BREATHING MANOEUVRE IN NEBULISED THERAPIES
Carolina Dantas and Ulf Krueger highlight the importance of the breathing manoeuvre in nebulised therapies – and describe a small study designed to test the effectiveness of patient feedback technology when it comes to guiding the inhalation manoeuvre. 
TRANSFORMING PHARMA MANUFACTURING TO DRIVE SUSTAINABILITY AND COST EFFICIENCY
EXPERT VIEW
Michael Astle
TRANSFORMING PHARMA MANUFACTURING TO DRIVE SUSTAINABILITY AND COST EFFICIENCY
Michael Astle, Gareth Jenkins and Edward Mayo explore current strategies to reduce carbon emissions and drive cost efficiency throughout the healthcare industry.
ENVIRONMENTAL DRIVERS FOR CHANGE IN DRUG DELIVERY DEVICES
EXPERT VIEW
Will Morris
ENVIRONMENTAL DRIVERS FOR CHANGE IN DRUG DELIVERY DEVICES
Will Morris discusses the positive changes that have occurred when it comes to environmental sustainability in the medical industry, in the context of examining what more can be done.
SHAPING A SUSTAINABLE BIOPHARMA INDUSTRY
EXPERT VIEW
Jimin Han
SHAPING A SUSTAINABLE BIOPHARMA INDUSTRY
Jimin Han delves into the intricate landscape of sustainability challenges within the biopharma industry and explores the innovative solutions that are steering drug development toward a greener future.
HOW LIFECYCLE ASSESSMENT SUPPORTS INSIGHT-DRIVEN SUSTAINABLE DESIGN
EXPERT VIEW
Paramesh Natarajan
HOW LIFECYCLE ASSESSMENT SUPPORTS INSIGHT-DRIVEN SUSTAINABLE DESIGN
Paramesh Natarajan, Shadi Bavar and Charlie Dean present the case for using screening lifecycle assessments to lead into more detailed targeted and comprehensive lifecycle assessments focused on the areas of greatest environmental impact, using a screening lifecycle assessment of a hypothetical body-worn injector as an example.
“A CHILD IS NOT A SMALL ADULT”: CHALLENGES AND SOLUTIONS IN DEVELOPING DRUG DELIVERY DEVICES FOR CHILDREN
EXPERT VIEW
Tom Oakley
“A CHILD IS NOT A SMALL ADULT”: CHALLENGES AND SOLUTIONS IN DEVELOPING DRUG DELIVERY DEVICES FOR CHILDREN
Tom Oakley and Heather Jameson consider the main differences in developing therapies and drug delivery devices for children and babies when compared with adults.
IDENTIFYING AND OVERCOMING THE CHALLENGES OF INJECTABLE COMBINATION PRODUCT EVOLUTION
EXPERT VIEW
David DeSalvo
IDENTIFYING AND OVERCOMING THE CHALLENGES OF INJECTABLE COMBINATION PRODUCT EVOLUTION
David DeSalvo considers some potential challenges that the rapid evolution of autoinjectors (and combination product injectables in general) raises, along with how the industry can successfully address this cycle of reinvention.
INJECTING INNOVATIVE SOLUTIONS INTO CONNECTED DELIVERY DEVICES
EXPERT VIEW
Roger Bohannan
INJECTING INNOVATIVE SOLUTIONS INTO CONNECTED DELIVERY DEVICES
Roger Bohannan discusses the capabilities and design challenges of connected drug delivery devices.
INCORPORATING MOTION DESIGN AT EARLY STAGES OF WEARABLE INJECTOR DEVELOPMENT
EXPERT VIEW
Dave Beckstoffer
INCORPORATING MOTION DESIGN AT EARLY STAGES OF WEARABLE INJECTOR DEVELOPMENT
Dave Beckstoffer discusses the often overlooked importance of including motion system design considerations from the very earliest stages of wearable injector development, and how doing so can reduce costs, shorten timelines and improve patient outcomes.
DIRECTIONS FOR WEARABLE ON-BODY INJECTOR SYSTEMS AND BEYOND
EXPERT VIEW
Matt Parker
DIRECTIONS FOR WEARABLE ON-BODY INJECTOR SYSTEMS AND BEYOND
Matt Parker, Karthik Chellappan and David Cottenden discuss the current state of play for large-volume injection and look into the challenges that on-body delivery systems currently in development will need to overcome to find success in a changing marketplace.
WOULD YOU LIKE TO GO LARGE? KEY CONSIDERATIONS FOR LARGE-VOLUME INJECTORS
EXPERT VIEW
Malcolm Boyd
WOULD YOU LIKE TO GO LARGE? KEY CONSIDERATIONS FOR LARGE-VOLUME INJECTORS
Malcolm Boyd discusses the factors that need to be considered early in the development of large-volume injectors, which will have a major influence on the performance, usability and cost of a device.
REUSABLE WEARABLE INJECTORS: LESSONS FROM IN VITRO DIAGNOSTICS
EXPERT VIEW
Thomas James
REUSABLE WEARABLE INJECTORS: LESSONS FROM IN VITRO DIAGNOSTICS
Thomas James explores how insights from the development of successful in vitro diagnostic instruments can help guide the evolution of wearable injectors.
DFM & DFA: THE DIFFERENCES, BENEFITS AND HOW TO IMPLEMENT THEM
EXPERT VIEW
Phil Sampey
DFM & DFA: THE DIFFERENCES, BENEFITS AND HOW TO IMPLEMENT THEM
Phil Sampey discusses the principles associated with design-for-manufacture (DFM) and design-for-assembly (DFA) methodologies as applied to drug delivery device design, giving an overview of what each involves and key areas of focus to ensure that the full benefits of these approaches can be realised.
ENTERING THE UK MARKET: A GUIDE FOR US MEDICAL DEVICES COMPANIES
EXPERT VIEW
Matthew Burton
IMed Consultancy
ENTERING THE UK MARKET: A GUIDE FOR US MEDICAL DEVICES COMPANIES
Matthew Burton discusses the new EU Medical Device Registration and offers a guide for the UK Responsible Person within companies.
THE POTENTIAL OF CONNECTIVITY AND MONITORING IN MESH NEBULISERS
EXPERT VIEW
Dr Carolina Dantas
THE POTENTIAL OF CONNECTIVITY AND MONITORING IN MESH NEBULISERS
Carolina Dantas and Ulf Krueger review the current connectivity and remote monitoring capabilities in mesh nebulisers – and their potential to impact patients’ healthcare journeys and the clinical development of inhaled therapies.
THE IRONIES OF AUTOMATION: LESSONS FOR REMOTE PATIENT MONITORING
EXPERT VIEW
Dan Lock
THE IRONIES OF AUTOMATION: LESSONS FOR REMOTE PATIENT MONITORING
Dan Lock considers how to overcome potential pitfalls and make the most of remote patient monitoring for the benefit of both patient care and clinical trials.
MODIFIED-RELEASE MICROSPHERES: MAXIMISING COATING INTEGRITY AND OPTIMISING RELEASE
EXPERT VIEW
Dr Jonathan Cape
MODIFIED-RELEASE MICROSPHERES: MAXIMISING COATING INTEGRITY AND OPTIMISING RELEASE
Jonathan Cape discusses development considerations and workflows to select optimal enteric coat weights for modified release microspheres – balancing performance considerations with API stability and the excipient burden to patients.
INCREASE PRODUCTION SUCCESS THROUGH TABLET DESIGN TECHNIQUES
EXPERT VIEW
Richard Ball
INCREASE PRODUCTION SUCCESS THROUGH TABLET DESIGN TECHNIQUES
Richard Ball considers the important features of tablet design and discusses its importance to the mass production of tablets.
HARD CAPSULES: A HOLISTIC APPROACH FOR ORAL DRUG DELIVERY AND FORMULATION
EXPERT VIEW
Dr Jnanadeva Bhat
HARD CAPSULES: A HOLISTIC APPROACH FOR ORAL DRUG DELIVERY AND FORMULATION
Jnanadeva Bhat and Manali Dalvi discuss how advances in capsule technology as an oral drug delivery method have opened up new avenues for the development of more effective and patient-friendly drugs.
ENSURING PATIENT SAFETY AMIDST MEDICAL DEVICE REGULATION DELAYS WITH PMS
EXPERT VIEW
Timothy Bubb
ENSURING PATIENT SAFETY AMIDST MEDICAL DEVICE REGULATION DELAYS WITH PMS
Timothy Bubb discusses the five steps to setting up an effective post-market surveillance process.
DESIGNING FOR USABILITY IN EMERGENCY-USE COMBINATION PRODUCTS
EXPERT VIEW
Thomas James
DESIGNING FOR USABILITY IN EMERGENCY-USE COMBINATION PRODUCTS
Thomas James highlights the importance of early user engagement, as well as continuous refinement of information and workflow design, for efficient development of drug-device combination products for emergency use.
Top